TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Borderline ovarian tumours
Key Statistics
- 10–20% — Of epithelial ovarian neoplasms are BOTs
- 99.7% — 5-Yr survival, FIGO stage i
- 2–24% — Recurrence rate range
Don't-miss facts
-
Normal CA125 does NOT exclude a BOT; no marker or imaging test can reliably separate benign/BOT/malignant disease
-
SBOT → cystectomy; MBOT → adnexectomy (appendicectomy only if macroscopically abnormal); full surgical staging recommended for all early-stage BOTs
-
Micropapillary/cribriform SBOT pattern = LGSOC precursor, ↑invasive implants/lethal recurrence; invasive implants = reclassify as LGSOC
-
No adjuvant chemo/radiotherapy role in BOT (Cochrane 2010); FSA concordance only 66–73% – rely on full staging, not FSA
-
Recurrence 2–24% (invasive only 0.5–3.8%), can occur >10 years later → follow up beyond 5 years; manage recurrence with secondary surgery
-
Fertility-sparing surgery/ART not contraindicated and does not worsen survival despite ↑recurrence risk; no advised delay before ART
-
MBOT: HRT recommended if menopausal <45y; SBOT with poor-prognosis histology (micropapillary/implants/microinvasion) – no HRT recommendation, discuss at menopause MDT
-
BOT in pregnancy: TVUSS first line; MRI (no gadolinium) from 12 weeks if indeterminate; laparoscopic approach preferred
Surgery at a glance
SBOT: cystectomy (bilateral option if bilateral) MBOT: adnexectomy ± cystectomy if bilateral
No routine lymphadenectomy or adjuvant therapy
Abbreviation Key
- BOT — borderline ovarian tumour
- HE4 — human epididymis protein 4
- OC — ovarian cancer
- CEA — carcinoembryonic antigen
- SBOT — serous borderline ovarian tumour
- α-FP — alpha-fetoprotein
- MBOT — mucinous borderline ovarian tumour
- β-HCG — beta-human chorionic gonadotrophin
- LGSOC — low-grade serous ovarian carcinoma
- LDH — lactate dehydrogenase
- FIGO — International Federation of Gynaecology and Obstetrics
- MDT — multidisciplinary team
- TVUSS — transvaginal ultrasound scan
- BSO/USO — bilateral/unilateral salpingo-oophorectomy
- IOTA — International Ovarian Tumour Analysis
- FSA — frozen section analysis
- ADNEX — Assessment of Different Neoplasms in the Adnexa
- ART — assisted reproductive technology
- O-RADS — Ovarian Adnexal Reporting and Data Systems
- HRT — hormone replacement therapy
- CA125 — cancer antigen 125
- NICE — National Institute for Health and Care Excellence
- CA19-9 — carbohydrate antigen 19-9
- RCOG — Royal College of Obstetricians and Gynaecologists
- BGCS — British Gynaecological Cancer Society
- ESGO/ESHRE/ESGE — European gynae- oncology/reproductive/endoscopy societies
- CNGOF — French College of Obstetricians & Gynaecologists
Source: Baker-Rand H et al. Borderline ovarian tumours. The Obstetrician & Gynaecologist 2025;27:321–331. doi:10.1111/tog.70007
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).